Posts Tagged ‘Novo Nordisk’

Cana/Phen: Unlocking a Potential New Drug Combination

March 30, 2017 — A new study in Diabetes Care provides tantalizing new data on a potential new combination drug for obesity: cana/phen. The study compared a combination of 300 mg of canagliflozin and 15 mg phentermine to each drug alone and to placebo. It was a randomized, controlled study that lasted 26 weeks. The combination was more effective than […]

A Rough Ride Despite Saxenda’s Success

October 31, 2016 — Over the last four years, four new obesity meds gained approval and only one lived up to expectations in the marketplace – the Saxenda brand of liraglutide 3 mg from Novo Nordisk. The company reported quarterly results last week. Saxenda sales, growing impressively, are on track to surpass $200 million for the year. Net profit for […]

Elusive Billions for Obesity Care

May 2, 2016 — A recent headline in Wired shouted it out: “Diabetes drug that also treats obesity could make billions.” What followed was a mostly reasonable discussion of the risks and benefits of obesity treatment in the jocular tone typical of Wired. Alexa Kurzius explains her assessment of the potential for Saxenda (liraglutide) for obesity: Initially, weight loss was just […]

Confusion and Progress in Obesity Care

April 15, 2016 — Ample confusion and progress can be found right now in the work of developing and delivering new medications for obesity care. Though we have some good options for treating obesity, we have a tremendous gap of unmet need between the extremes of behavioral therapy and surgical treatments for obesity. Though four new obesity meds have […]

Liraglutide CV Outcomes: A Milestone for Diabetes and Obesity

March 7, 2016 — A major new study shows that people treated with liraglutide for type 2 diabetes have fewer strokes, heart attacks, and deaths from heart disease. Six years ago, cardiovascular outcomes had doctors scratching their heads about diabetes and obesity drugs. A hearing on a flawed outcome study with sibutramine resulted in its withdrawal from the market. […]

Being Different in Diabetes and Obesity

December 11, 2015 — Being different can be uncomfortable and, sometimes, rewarding. A new review in the Annals of Internal Medicine finds only small differences between a rising crop of new, once-weekly drugs for diabetes called GLP-1 agonists. The investigators found a lot of similarities between the outcomes with these drugs, along with some differences in side effects, body weight, […]

Halfway There in Developing Obesity Care?

August 9, 2015 — Progress in developing obesity care options is very encouraging, and at the same time frustrating. Friday, Novo Nordisk reported on early results from introducing Saxenda — the fourth new obesity treatment in as many years — into the U.S. Uptake is encouraging, with prescriptions that are growing steadily at a volume comparable to other recent introductions. For […]

Mixed Reaction to Positive Obesity Results for Liraglutide

March 28, 2013 — Novo Nordisk announced positive results last week from a one-year, double-blind, placebo-controlled, phase 3 clinical trial of the potential for liraglutide to reduce and maintain weight in people with type 2 diabetes and excess weight or obesity. Liraglutide is a once-daily injection used to treat type 2 diabetes that has been available in the U.S. […]